System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish

PubMed: 40800581 DOI: 10.34133/research.0836

New Insights into Monocyte-Derived Macrophages in Glioblastoma.

Research (Wash D C) 8:0836

Authors: Xuetong Li, Wei Gao, Xinmiao Long, Minghua Wu

Affiliations

  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, China.
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
  • The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, China.
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China. The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, China. Xiangya School of Public Health, Central South University, Changsha, China.

Abstract

Glioblastoma (GBM) is a highly aggressive brain tumor characterized by an immunosuppressive microenvironment that importantly contributes to treatment resistance. Monocyte-derived macrophages (MDMs), which comprise approximately 50% of the cellular population within the GBM microenvironment, represent a major subset of tumor-associated macrophages. These cells drive tumor progression by promoting angiogenesis, immune evasion, and the phenotypic transformation of tumor cells. MDM infiltration is mediated by specific signaling pathways and regulated by the disruption of the blood-brain barrier and tumor-associated hypoxia. Recent technological advances have uncovered substantial heterogeneity among macrophages, including hypoxia-induced, lipid-metabolizing, phagocytic, and interferon-activated subtypes. This functional diversity is shaped by tumor-specific genetic alterations and metabolic reprogramming. Therapeutic approaches focusing on MDMs include inhibiting their recruitment, enhancing phagocytic activity, employing genetically engineered macrophage, and modulating metabolic pathways. While preclinical studies suggest that these approaches may improve efficacy when combined with immune checkpoint inhibitors, the dynamic spatiotemporal heterogeneity and adaptability of macrophages within the tumor microenvironment remain substantial therapeutic challenges. Future development in combination therapies, integrating single-cell multi-omics, spatial metabolic profiling, and targeted interventions, will be critical to precisely modulate MDMs, overcome immune tolerance, and improve patient outcomes.

MeSH

Cells, Monocytes, Macrophages, Brain, Neoplasms, Hypoxia, Glioblastoma, Therapeutics